Lupin Receives US FDA Approval For Mycophenolic Acid

Pharma major Lupin Limited (Lupin) announced the approval of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. Lupin’s alliance partner Concord Biotech Limited (Concord) has received an approval for Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Myfortic® Delayed Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.

Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, are indicated for:

– Prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant.

– Use in combination with cyclosporine and corticosteroids.

Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg (RLD: Myfortic®) had an annual sales of approximately USD 174 million in the U.S. (IQVIA MAT Sept ember 2019).

Shares of LUPIN LTD. was last trading in BSE at Rs.766.1 as compared to the previous close of Rs. 754. The total number of shares traded during the day was 40436 in over 1103 trades.

The stock hit an intraday high of Rs. 767.55 and intraday low of 754.1. The net turnover during the day was Rs. 30848598.-Equity Bulls